Nelfinavir is an orally bioavailable inhibitor of the HIV-1 protease (Ki =2 nM) that is used in combination with HIV reverse transcriptase inhibitors for the treatment of HIV infection. Nelfinavir demonstrates anti-cancer activity, selectively preventing the growth of HER2-positive breast cancer cells in vitro by inhibiting Hsp90 (IC50 = 3.1 μM).
